ReviewCureus2025
Electromagnetic Cell Current Modulation As Adjunctive Therapy in HIV: A Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the success of antiretroviral therapy (ART), people living with HIV continue to face challenges such as chronic immune activation, oxidative stress, mitochondrial dysfunction, and latent reservoirs that prevent complete immune restoration or cure. These persistent gaps highlight the research problem: the need for safe and effective adjunctive strategies that go beyond viral suppression. The objective of this review is to critically evaluate Electromagnetic Cell Current Modulation (ECCM) as a potential adjunctive therapy in HIV, integrating mechanistic evidence, preclinical data, and emerging clinical insights. Using a narrative synthesis approach, the review examines studies across cellular, animal, and early patient-level investigations, and compares ECCM with other adjunctive modalities. Key findings suggest that ECCM may modulate cytokine signaling, enhance mitochondrial activity, reduce inflammation, and potentially influence viral latency. Small pilot studies have reported improvements in CD4 counts, symptom burden, and quality of life. The implications are substantial: if validated, ECCM could complement ART by targeting host-level dysfunctions that drive morbidity. The conclusion emphasizes the urgent need for standardized protocols, rigorous animal studies, and controlled clinical trials to determine the safety, efficacy, and scalability of this treatment. Although still early in development, ECCM offers a scientifically plausible and clinically relevant avenue for future HIV care innovation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.